Raymond James Downgrades Verastem (VSTM) to Outperform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Raymond James Downgrades Verastem (VSTM) to Outperform

Verastem Stops Enrollment Due to Futility in the COMMAND Study of VS-6063 for the Treatment of Malignant Pleural Mesothelioma

September 28, 2015 7:00 AM EDT

No difference in VS-6063 versus placebo in either the intent to treat population or patients with Merlin-low tumors

Company to Host Conference Call Today at 8:30 AM ET

BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the Company has stopped enrollment in the Phase 2 registration-directed, double-blind, placebo-controlled study (COMMAND) of VS-6063 for patients with mesothelioma. The decision to stop enrollment for futility followed a Data Safety... More